Compare ClearPoint Neuro Inc (CLPT) vs ING Groep NV (ING) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs ING Groep NV — how do they compare? ClearPoint Neuro Inc trades at $15.7 (market cap $478.63M), while ING Groep NV trades at $32.76 (market cap $93.58B). The key difference: ING Groep NV is far larger — about 195.5× ClearPoint Neuro Inc's market cap, and ING Groep NV pays a 3.86% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | ING | |
|---|---|---|
Market Cap | $478.63M | $93.58B |
Sector | Health | Financials |
52-Week High | $29.60 | $32.96 |
52-Week Low | $8.66 | $22.45 |
Enterprise Value | $506.63M | — |
Dividend Yield | — | 3.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
ING trades at $32.30, down 0.28% on the day, with strong analyst support (62.5% buy ratings) and bullish technical signals. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $0.63 exceeding the $0.60 forecast. Revenue growth remains steady at $22.9B for 2025, while net income margin stands at 27.84%. Recent corporate developments include a new global subscription banking model and management board appointments.
The outlook remains positive given ING's earnings momentum, attractive valuation (P/E 12.95), and strategic initiatives. Key risks include negative operating cash flow trends and exposure to European banking sector volatility. With intrinsic value estimates around $34 from DCF analyses, the stock offers potential upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →
